Microbot Medical Inc. (MBOT)
NASDAQ: MBOT · Real-Time Price · USD
3.220
-0.070 (-2.13%)
At close: Sep 26, 2025, 4:00 PM EDT
3.200
-0.020 (-0.62%)
After-hours: Sep 26, 2025, 7:58 PM EDT

Company Description

Microbot Medical Inc. is a medical device company that focuses on transforming endovascular procedures through advanced robotic technology.

The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, endovascular, and neurovascular operations.

It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter.

The company has a collaboration agreement with Corewell Health for the development of LIBERTY endovascular robotic system; and Emory University, in connection with autonomous robotics in endovascular procedures.

Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts

Microbot Medical Inc.
Microbot Medical logo
CountryUnited States
Founded2010
IndustryMedical Instruments & Supplies
SectorHealthcare
Employees20
CEOHarel Gadot

Contact Details

Address:
175 Derby Street, Bld. 27
Hingham, Massachusetts 02043
United States
Phone781-875-3605
Websitemicrobotmedical.com

Stock Details

Ticker SymbolMBOT
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0000883975
CUSIP Number59503A204
ISIN NumberUS59503A2042
Employer ID94-3078125
SIC Code3841

Key Executives

NamePosition
Harel GadotCo-Founder, President, Chief Executive Officer and Chairman
Rachel VakninChief Financial Officer
Dr. Simon Sharon MBA, MScChief Technology Officer and GM of Microbot Israel
Dr. Juan Diaz-CartelleChief Medical Officer
Michal AhuviaDirector of Operations
Christina BaileyVice President of Sales
Naama MoavVice President of Human Resources
Michael LytleHead of Sales Operations and Analytics

Latest SEC Filings

DateTypeTitle
Sep 23, 20258-KCurrent Report
Sep 19, 20258-KCurrent Report
Sep 16, 20258-KCurrent Report
Sep 9, 20258-KCurrent Report
Sep 8, 20258-KCurrent Report
Aug 27, 20258-KCurrent Report
Aug 25, 20258-KCurrent Report
Aug 20, 20258-KCurrent Report
Aug 12, 2025SCHEDULE 13G/AFiling
Aug 12, 202510-QQuarterly Report